Nivolumab Clinical Research Studies
Clinical research studies are now enrolling for the investigational compound nivolumab (BMS-936558) in certain cancer types. Click on one or more of the options to see if there is a participating study site in your area that you can contact directly.
Renal Cell Carcinoma (Kidney Cancer)
- Study of BMS-936558 Compared to Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
Please check back for future updates on lung cancer studies.
- Study of BMS-936558 Compared to Investigator's Choice in Advanced (Unresectable/Metastatic) Melanoma Patients Progressing Post-Anti-CTLA-4 Therapy
- Study of Nivolumab or Nivolumab Plus Ipilimumab Compared to Ipilimumab Alone in Previously Untreated Advanced Melanoma
- Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Select Advanced Solid Tumors
Please note, not all studies may be enrolling at this time. Check back often for updates.